Cees de Jong

Cees de Jong currently serves as Chairman of Novonesis, a joint venture formed in 2024 from Chr. Hansen and Novozymes, and has held the position of Chairman at Meatable and Oterra since 2021 and 2021, respectively. Previously, Cees de Jong was Chairman of Novozymes from February 2020 to January 2024, Vice Chairman of the Supervisory Board, and Chairman of Mediq and ForFarmers N.V. between 2018 and 2022, and 2018 and 2021, respectively. Cees de Jong also held leadership roles at Chr. Hansen A/S as President and CEO, and at Crucell as COO and Member of the Board, where significant revenue growth was realized. Education includes an MBA from Rotterdam School of Management, Erasmus University, and an MD from Erasmus University Rotterdam.